Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
VenoStent
AddedFeb 15, 2024
UpdatedJun 18, 2026
VenoStent

VenoStent

Series A

VenoStent: Enhancing vascular surgeries with bioabsorbable polymer wraps.

HQ
Houston, TX, US
Founded
2017
Accelerator
Y Combinator logoY CombinatorS20
Overview
Compare
Fundraising
Employees
Website

VenoStent was founded with the core mission of enhancing vascular surgeries through innovative medical solutions. The company's vision is to significantly improve patient outcomes in dialysis and bypass surgeries by reducing failure rates. VenoStent's flagship product, SelfWrap, is a bioabsorbable, flexible vascular wrap designed to support blood vessels during surgery, particularly in renal dialysis access. Their market focus is on patients undergoing dialysis and other vascular surgeries, addressing a critical need in the healthcare sector.

Notable affiliated people and investors include experts in the medical and biotech fields, though specific names are not provided. Key achievements for VenoStent include the development and clinical trials of SelfWrap, demonstrating its potential to reduce dialysis access site failures. Overall, VenoStent's impact lies in its innovative approach to improving surgical outcomes, potentially saving lives and reducing healthcare costs associated with failed vascular procedures.

VenoStent - Similar Companies

Voyager Biomedical logo

Voyager Biomedical

Vascular Therapies logo

Vascular Therapies

vasculartx.com

Vascular Dynamics logo

Vascular Dynamics

Access Vascular logo

Access Vascular

InnoVein logo

InnoVein

Venova Medical logo

Venova Medical

venovamed.com

Novostent logo

Novostent

Vena Medical logo

Vena Medical

venamed.ca

PolyVascular logo

PolyVascular

polyvascular.com

Bluegrass Vascular Technologies logo

Bluegrass Vascular Technologies

Venarum Medical logo

Venarum Medical

Venock logo

Venock

venock.com

Healionics logo

Healionics

healionics.com

Vena Vitals logo

Vena Vitals

venavitals.com

Bioabsorbable Therapeutics logo

Bioabsorbable Therapeutics

VenoStent - Quick Facts

Who are VenoStent's competitors?

Companies similar to VenoStent include Voyager Biomedical, Vascular Therapies, Vascular Dynamics and Access Vascular.

When was VenoStent founded?

VenoStent was founded in 2017.

Where is VenoStent's headquarters located?

VenoStent's headquarters is located in Houston, TX, US.

When was VenoStent's last funding round?

VenoStent's most recent funding round was for $16M (USD) in July 2023.

How much has VenoStent raised to-date?

As of Jul 31, 2023, VenoStent has raised a total of $22.2M (USD).

How many employees does VenoStent have?

VenoStent has 13 employees as of Feb 5, 2024.

VenoStent - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthcare
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified